Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2/3 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2Vomiting 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Postoperative Nausea and Vomiting 1Neoplasms 1Neoplasm Metastasis 1Mesothelioma 1Leukemia, Hairy Cell 1Carcinoma 1Breast Carcinoma In Situ 1

Interventions

Trastuzumab 243Paclitaxel 193Cyclophosphamide 158Docetaxel 134Letrozole 113Capecitabine 113Fulvestrant 106Doxorubicin 103Bevacizumab 87Carboplatin 81exemestane 80Anastrozole 79Lapatinib 70Tamoxifen 69Albumin-Bound Paclitaxel 57palbociclib 54pertuzumab 53Taxes 51Gemcitabine 50Radiotherapy 46eribulin 43pembrolizumab 41Everolimus 41Ado-Trastuzumab Emtansine 41Vinorelbine 38130-nm albumin-bound paclitaxel 35ixabepilone 32Epirubicin 28pegfilgrastim 25liposomal doxorubicin 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Breast Neoplasms × Famotidine × Clear all
NCT02473042 2025-12-05

Intraoperative Acupoint Stimulation to Prevent Post-Operative Nausea and Vomiting (PONV)

M.D. Anderson Cancer Center

Phase NA Completed
188 enrolled 11 charts
Breast

Breast Neoplasms, Vomiting, Postoperative Nausea and Vomiting

NCT04862585 2025-08-20

Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel

Ohio State University Comprehensive Cancer Center

Phase 2/3 Completed
130 enrolled 8 charts
Breast

Breast Carcinoma In Situ, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡